This study looks at how well a medicine called **Cabotegravir (CAB)** works to prevent HIV in Black cisgender and transgender women in the United States. _Cabotegravir_ is a type of pre-exposure prophylaxis (PrEP), a medicine taken to prevent getting HIV. The study will find out how easy it is to use, how well it works, and what makes it hard or easy for people to use. There are two groups in the study: **Patient Study Participants (PSPs)**, who will take the medicine, and **Staff Study Participants (SSPs)**, who will help give the medicine and check on the patients.
- The study is for adults 18 years or older who are HIV negative.
- You cannot join if you're in another study or if you're a cis- or transgender male.
- Participants must be African American/Black and female at birth or identify as a transgender female.
Participants need to be able to understand and agree to the study rules. They will get CAB PrEP from a provider who thinks it is right for them. This study helps understand how to best offer CAB PrEP to those who need it.